In Brief This Week: Agilent Technologies; Diagnocure; KineMed, Pfizer; PositiveID; SomaLogic | GenomeWeb

NEW YORK (GenomeWeb) – Agilent Technologies said this week that it has mad an adjustment to its second quarter 2014 GAAP net income. The firm said that it has lowered that figure to $139 million, or $.41 per share, from a previously reported $150 million, or $.45 per share. Agilent said the change was the result of an out-of-period adjustment for tax expense. It added that its Q2 2014 non-GAAP net income was unchanged at $244 million, or $.72 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.